The FDA Wants to Limit Where Compounded GLP-1s Come From
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
The FDA has proposed leaving three ingredients off a list that large-scale compounding facilities need in order to make medications from raw active ingredients. In its own words, the notice "identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide" (Federal Register). The public comment period closed on July 30, 2026. Nothing has changed yet, and one compounding pathway would remain open even if the proposal becomes final.
Who This Helps
This is for you if you currently get a compounded GLP-1 product through a telehealth provider or a pharmacy, if you are weighing that option against a brand-name prescription, or if you have seen headlines saying compounded versions are ending and want to know what is actually being decided. It also helps if you are trying to understand why your pharmacy and your neighbor's pharmacy might be governed by different rules.
Does This Affect Your Medication Right Now?
No. This is a proposal that is still in process, and no rule has been finalized.
Two things are worth holding onto while you read the rest. First, the FDA has set no deadline for itself and has announced no target date, because the law creating this list does not impose one. Second, the proposal is about one specific manufacturing route, which is compounding that starts from raw active ingredients at a large-scale facility. It does not by itself address every kind of compounding, and a separate pathway for individual patients works differently.
The FDA also has not said how many people would be affected, and has not published any enforcement timeline.
What Is Actually Being Proposed
The FDA published its announcement on April 30, 2026, and the formal notice appeared in the Federal Register on May 1, 2026 under docket number FDA-2018-N-3240 (FDA).
The reason given was not a finding about harm. The agency wrote that "After evaluating the nominations for these three substances, the FDA did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances." Clinical need is a specific legal test, and the whole decision turns on it.
The comment period was originally set to close June 30, 2026 (Federal Register). The FDA extended it by 30 days, to July 30, 2026, after a request for 60 days. Its explanation for splitting the difference is a useful signal about pace: the agency said a 30-day extension "appropriately balances allowing adequate time for interested persons to submit comments with avoiding significant delay of Agency action on these important issues" (Federal Register).
What "Clinical Need" Means, and Why It Decided This
The list in question exists because federal law lets a large-scale compounder work from raw active ingredients only in certain circumstances. To add a substance, the FDA asks two questions (Federal Register):
- Is there a basis to conclude that something about the FDA-approved product makes it medically unsuitable for certain patients, and that the compounded version is meant to address that specific thing?
- Is there a basis to conclude that the compounded product has to be made from raw active ingredients rather than starting from an already-approved drug?
That framing explains several arguments the FDA turned down. On supply, the agency wrote that it "does not interpret supply issues, such as backorders, to be within the meaning of 'clinical need' for compounding with a bulk drug substance." On cost and ease of use: "FDA does not consider convenience in administering a particular compounded drug product (e.g., a ready-to-use form) or the cost of the compounded drug product as compared with an FDA-approved drug product when assessing 'clinical need.'" And on preference, the agency said that what a nomination described as patient preference for a different formulation "does not mean that the formulation of the approved drug is medically unsuitable."
The agency applied the same reasoning to a specific ingredient argument, writing that it "has not identified any data or information to suggest that propylene glycol would cause a drug product containing semaglutide to be medically unsuitable."
What this means for you: the test the FDA used asks whether approved products are medically unsuitable for some patients, not whether compounded products are safe or effective. Cost is a real problem for many people, and it is also not one of the factors this particular legal test allows the agency to weigh.
The Two Kinds of Compounding Pharmacies, and Why the Difference Matters Now
This proposal lands on one of these categories and not the other, so the distinction between the two means understanding what pharmacy can continue compounding and which can’t.
503A pharmacies:
- Compound for an individual patient based on a prescription
- Overseen day to day by state boards of pharmacy, with the FDA retaining certain authorities
- Not the subject of this proposal
503B outsourcing facilities:
- Register with the FDA as outsourcing facilities
- Overseen and inspected by the FDA on a risk-based schedule, and subject to current good manufacturing practice requirements
- The subject of this proposal
The FDA describes the oversight split directly, noting that "Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities," while facilities registered under 503B "are primarily overseen by FDA and inspected by FDA according to a risk-based schedule" (FDA).
Both operate inside legal frameworks. If you want the longer version of how these two categories differ, we have a full explainer on 503A versus 503B compounding pharmacies.
What Would Still Be Possible for an Individual Patient
Federal law carves out room for a compounded medication that is genuinely different for a specific person, and that room does not close under this proposal.
The statute says the phrase describing a copy of a commercially available drug "does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug" (FDA).
The FDA gives examples of what can count. One is an inactive ingredient: a product "compounded without a particular inactive ingredient may produce a significant difference for a patient who has an allergy to the inactive ingredient in the commercially available drug product." Another is strength, where the agency shows an acceptable prescription note as "6 mg, patient needs higher dose" when the approved product only comes in 5 mg.
What this means: the judgment in what is compounded belongs to your prescriber, for you specifically, and it has to be documented. What the law does not allow is routine production of something that amounts to a copy of an available approved drug.
There is also a separate route tied to drug shortages. The FDA notes that section 503B "separately provides for compounding from a bulk drug substance under the exemptions discussed above if the drug product compounded from the bulk drug substance is on the FDA drug shortage list at the time of compounding, distribution, and dispensing" (Federal Register). Shortages have driven this before, which is why the timeline in the next section matters. The FDA decides what goes on that shortage list, so this route is not one that patients or pharmacies can open themselves.
How We Got Here
The shortage era ended more than a year ago, and this proposal is the next step in a sequence rather than a sudden reversal.
The FDA resolved the tirzepatide shortage on December 19, 2024, and its enforcement flexibility for that ingredient ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. The semaglutide shortage resolved February 21, 2025, with corresponding dates of April 22, 2025 and May 22, 2025 (FDA).
So the delta this proposal would add is narrow. Shortage-based authority for these ingredients already ended in 2025. What would change is that the separate clinical-need route into large-scale compounding from raw ingredients would be formally closed for these three, rather than left open as an unanswered nomination.
Why So Many People Have a Stake in This
Compounded products are not a niche. Gallup surveyed 5,065 US adults between May 28 and June 5, 2026 and found that 11% currently take a GLP-1 medication, up from 3% in 2024 (Gallup).
Among people currently taking one, 19% use a compounded or custom-mixed version. Movement between the two runs mostly one way: 35% of current compounded users had switched over from a brand name, while 10% of current brand-name users had switched over from a compounded version. Among people who moved from a brand name to a compounded version, 66% named cost or insurance coverage as their main reason.
One finding cuts against the assumption that people settle for compounded products reluctantly. About four in ten compounded users, 39%, described their medication as extremely effective, compared with 32% of brand-name users. That is self-reported experience rather than a trial result, and it is worth knowing when you read that patients are simply choosing the cheaper option.
Is Anyone Challenging This in Court?
Not this proposal, as of early August 2026.
There has been litigation over compounded GLP-1s, and it concerned a different decision. The Outsourcing Facilities Association sued the FDA in the Northern District of Texas over the removal of tirzepatide from the shortage list, in case number 4:24-cv-00953, filed October 7, 2024 (Justia). The court denied the request for a preliminary injunction on March 5, 2025 (Frier Levitt). A parallel case over semaglutide, number 4:25-cv-00174, was filed February 24, 2025.
Those cases were about shortage-list removals rather than this list. No lawsuit over this bulks-list proposal had been filed as of early August 2026.
What You Can Do Now
Nothing about this proposal requires you to change medications today, and no part of it tells you to move away from a compounded product.
A few things are useful regardless of how it resolves:
- Ask which pharmacy actually makes your medication, and whether it is a 503A pharmacy or a 503B outsourcing facility. Your provider should be able to say.
- Ask what is in the vial besides the active ingredient. Some formulations include additives, and knowing yours matters if you have sensitivities. Our pharmacy listings now let you search by additive.
- Verify the pharmacy's license with the state board where it operates.
- If cost is what brought you to a compounded product, that is worth saying out loud to your prescriber, because it shapes which options make sense to discuss.
If you want to compare providers, including compounding options and the pharmacies they work with, our provider comparison walks you through a few questions about what you are looking for and points you toward telehealth providers that match. For background on how compounding pharmacies are regulated in the first place, see our guide to what a compounding pharmacy is and why it matters.
Final Takeaway
A proposal is not a rule, and this one has not become one. The FDA has asked whether large-scale facilities have a clinical need to make these three ingredients from raw material, and it has said, for now, that it does not see one. Comments closed at the end of July and the agency is reviewing them with no announced deadline. The route for a genuinely individualized prescription, judged and documented by your prescriber, is not part of what is being decided. Nothing here says compounded medications are unsafe, and nothing here asks you to stop using one. The most useful thing you can do is know exactly who makes your medication and what is in it. That knowledge serves you no matter which way this lands.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Does this mean compounded GLP-1s are being banned?
No. The proposal addresses one specific route, which is large-scale compounding that starts from raw active ingredient at a registered outsourcing facility. It has not been finalized, and compounding for an individual patient based on a prescriber's documented judgment that the person needs something different is not part of this decision.
What is the 503B Bulks List?
It is a list of raw active ingredients that federal law allows outsourcing facilities to compound with when there is a clinical need to do so. If an ingredient is not on the list, a facility can still work with it when the finished medication appears on the FDA drug shortage list at the time of compounding, distribution and dispensing.
Did the FDA say compounded GLP-1 products are unsafe?
The proposal rests on a clinical need test, which asks whether FDA-approved products are medically unsuitable for certain patients and whether a compounded version would have to start from raw ingredient. The agency concluded it did not identify a clinical need. That is a different question from whether any product is safe, and the notice does not make a safety finding about compounded GLP-1 products.
When will the FDA make a final decision?
No date has been announced. The law that created this list does not set a deadline for the agency to finish, and the FDA has not committed to one. The comment period closed July 30, 2026, and the agency is reviewing what it received.
Why did the FDA say cost does not count?
Clinical need is defined narrowly in this context. The agency stated that it does not weigh the cost of a compounded product compared with an approved one, or the convenience of a particular form, when assessing clinical need. Cost may matter enormously to a patient and still fall outside what this specific legal test permits the agency to consider.
Sources
Keep Reading
B12, B6, niacinamide, glycine, benzyl alcohol: see what each GLP-1 additive does, the allergy risks, and how to search providers by additive.
An FDA panel backed 6 of 7 peptides for the compounding list. See the votes, what each was proposed to treat, and what has to happen next.
Canada is approving generic Ozempic, India already has. Here is what it means for US prices, when patents expire, and what you can actually do today.
Categories
Curated by
